Francis Fagnani

Bourg-la-reine, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Prognostic impact of the number and Temporality of heart failure Hospitalisations: Analysis of a National healthcare database.

Prognostic impact of the number and Temporality of heart failure Hospitalisations: Analysis of a National healthcare database.

Journal: International journal of cardiology. Heart & vasculature

Published: September 15, 2025

Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019-2023).

Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI®) in France: An analysis of the PMSI database over five years (2019-2023).

Journal: Revue neurologique

Published: December 16, 2024

Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database.

Clinical and Economic Burden of Patients With Haemophilia A and B in France: Analysis of a Nationwide Claims Database.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: November 04, 2024

Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study.

Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study.

Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Published: October 29, 2023

Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Journal: Advances in therapy

Published: October 31, 2022

Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Journal: Advances in therapy

Published: March 29, 2022

Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data.

Epidemiology and disease burden of tuberous sclerosis complex in France: A population-based study based on national health insurance data.

Journal: Epilepsia open

Published: January 28, 2022

Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.

Journal: Advances in therapy

Published: October 29, 2021

Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claims database analysis.

Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claims database analysis.

Journal: Bone

Published: November 20, 2020

Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.

Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.

Journal: Journal of medical economics

Published: January 14, 2020

Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.

Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.

Journal: Clinical and experimental rheumatology

Published: December 13, 2019

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.

Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study.

Journal: RMD open

Published: April 18, 2019

Showing 1-12 of 39

Last Updated: 09/26/2026